Breaking News Instant updates and real-time market news.

BRO

Brown & Brown

$34.64

-0.11 (-0.32%)

, SNAP

Snap

$14.14

0.12 (0.86%)

18:48
07/22/19
07/22
18:48
07/22/19
18:48

Fly Intel: After Hours Movers

UP AFTER EARNINGS: Brown & Brown (BRO) up 1.0%. ALSO HIGHER: Snap (SNAP) up 2.2% after being upgraded to Buy at Stifer and initiated with Buy at Rosenblat... Intel (INTC) up 1.3%, Qualcomm (QCOM) down 2.7% after WSJ report of Apple interest in Intel's smartphone model chip business. DOWN AFTER EARNINGS: Steel Dynamics (STLD) down 5.8%... Zions Bancorp (ZION) down 4.9%... Cadence Design (CDNS) down 1.1%, Synopsys (SNPS) down 7.7 in sympathy... Whirlpool (WHR) down 0.9%... TD Ameritrade (AMTD) down 0.6%. ALSO LOWER: Acadia Pharma (ACAD) down 15.3% after its phase 3 Pimavanserin trial in schizophrenia did not achieve primary endpoint statistical significance. Movers as of 18:30ET.

BRO

Brown & Brown

$34.64

-0.11 (-0.32%)

SNAP

Snap

$14.14

0.12 (0.86%)

INTC

Intel

$51.36

1.1 (2.19%)

QCOM

Qualcomm

$75.93

0.9 (1.20%)

STLD

Steel Dynamics

$31.55

0.09 (0.29%)

ZION

Zions Bancorp

$45.16

-0.95 (-2.06%)

CDNS

Cadence Design

$72.68

-0.21 (-0.29%)

SNPS

Synopsys

$135.42

0.41 (0.30%)

WHR

Whirlpool

$148.30

0.085 (0.06%)

AMTD

TD Ameritrade

$52.41

0.82 (1.59%)

ACAD

Acadia

$25.97

0.28 (1.09%)

  • 22

    Jul

  • 22

    Jul

  • 22

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 25

    Jul

  • 31

    Jul

  • 31

    Jul

  • 03

    Aug

  • 06

    Aug

  • 20

    Aug

  • 21

    Aug

  • 26

    Sep

  • 27

    Sep

BRO Brown & Brown
$34.64

-0.11 (-0.32%)

04/24/19
RHCO
04/24/19
NO CHANGE
Target $36
RHCO
Buy
Brown & Brown price target raised to $36 from $32 at SunTrust
SunTrust analyst Mark Hughes raised his price target on Brown & Brown to $36 and kept his Buy rating after its Q1 outperformance, also raising his FY20 EPS view by 4c to $1.54. The analyst notes that the organic growth outlook for the stock looks "incrementally positive" after the management forecast Retail segment organic topline expansion to be "slightly" better in Q2. Hughes also cites "continued benefit" for Brown & Brown from strong economy and improved pricing environment.
03/21/19
RHCO
03/21/19
NO CHANGE
Target $32
RHCO
Buy
Brown & Brown leads in value-add arena for insurers, says SunTrust
SunTrust analyst Mark Hughes kept his Buy rating and $32 price target on Brown & Brown after his travels with its management, saying the company CFO has highlighted the company's "leading position in the program management space" to investors. The analyst believes that in the National Programs division in particular, which accounts for a quarter of its revenue", Brown & Brown's captures up to 30% of earned premium vs. 10% normal commissions thanks to its broker partnerships. Hughes also sees "Insuretech" as a benefit to the company's National Programs, since "many of the new technology developments are targeting operational inefficiencies and should thus lower operating costs."
07/16/19
RHCO
07/16/19
NO CHANGE
Target $40
RHCO
Buy
Brown & Brown price target raised to $40 from $36 at SunTrust
SunTrust analyst Mark Hughes raised his price target on Brown & Brown to $40 and kept his Buy rating on the stock. The analyst says the company's Q2 results should benefit from improved fundamentals in the P&C space as well as in Florida, where re-insurance pricing and primary property rates are driven higher after recent losses in what was a "key" renewal period.
09/20/18
RHCO
09/20/18
NO CHANGE
Target $33
RHCO
Buy
Brown & Brown to continue organic growth trends, says SunTrust
SunTrust analyst Mark Hughes kept his Buy rating and $33 price target on Brown & Brown after its "first ever Investor Day" in New York, saying the management has expressed its intentions to drive organic growth with "new product initiatives and technology enhancements". The analyst also expects the company to continue executing its M&A strategy that is funded by cash flows, maintaining its "conservative leverage". Hughes further points to the company's wholesale brokerage business outperforming last year results and its National Programs segment outpacing the industry.
SNAP Snap
$14.14

0.12 (0.86%)

07/22/19
RSBL
07/22/19
INITIATION
Target $18
RSBL
Buy
Snap initiated with a Buy at Rosenblatt
Rosenblatt analyst Mark Zgutowicz started Snap with a Buy rating and $18 price target. Snap's current average revenue per user levels are well below social media peers, which provides room to "comfortably double" by 2023, Zgutowicz tells investors in a research note. In the near-term, the analyst believes the shares SNAP shares should rise on "modest tailwinds" from new advertising products and video content.
07/22/19
STFL
07/22/19
UPGRADE
Target $17
STFL
Buy
Snap upgraded to Buy from Hold at Stifel
Stifel analyst John Egbert upgraded Snap to Buy and raised his price target to $17 from $13.
07/22/19
STFL
07/22/19
UPGRADE
Target $17
STFL
Buy
Snap upgraded to Buy from Hold at Stifel
Stifel analyst John Egbert upgraded Snap to Buy and raised his price target to $17 from $13 ahead of its Q2 earnings tomorrow, saying the company's sales reorganization efforts were already reflected in its prior guidance and the daily active user checks for the quarter appear to be positive. The analyst contends that if the impact of the reorganization is limited, the management's prior guidance may prove to be conservative, adding that Snap's advertising products with large brands and direct response advertisers appear to be gaining traction.
07/15/19
MSCO
07/15/19
NO CHANGE
Target $13
MSCO
Underweight
Snap's 'impressive' turnaround already priced in, says Morgan Stanley
Morgan Stanley analyst Brian Nowak said he underestimated Snap's "impressive" turnaround and he raised his estimates after his analyses pointed to better growth in users, revenue and EBITDA. While he also raised his price target on the stock to $13 from $9, Nowak still believes that even if Snap hits his above-consensus estimates that long-term EBITDA valuation points to multiple compression and he keeps an Underweight rating on the shares.
INTC Intel
$51.36

1.1 (2.19%)

07/22/19
ATLE
07/22/19
INITIATION
Target $38
ATLE
Underweight
Intel initiated with an Underweight at Atlantic Equities
Atlantic Equities started Intel with a Underweight rating and $38 price target.
07/18/19
MZHO
07/18/19
DOWNGRADE
Target $37
MZHO
Neutral
AMD downgraded to Neutral from Buy at Mizuho
Mizuho analyst Vijay Rakesh downgraded AMD (AMD) to Neutral from Buy while raising his price target for the shares to $37 from $33. The chipmaker closed Wednesday down 25c to $33.60. The analyst continues to like AMD given its "solid" Ryzen/Rome portfolio and new product ramps, but he's downgrading the shares after a "stellar" 80% rally year-to-date. With the stock at a 10-year high, upside in the second half of 2019 will be more limited, Rakesh tells investors in a research note. This will be due to the PC pull-in that occurred during the first half of 2019, slower Rome ramps in the second half, and pricing pressure from Intel (INTC), contends the analyst. Rakesh says he'd revisit AMD shares at a more attractive entry point since its long-term roadmap "is still intact."
07/17/19
NOMU
07/17/19
NO CHANGE
Target $65
NOMU
Buy
Nomura Instinet reiterates Buy rating on Intel ahead of June quarter results
Nomura Instinet analyst David Wong reiterates a Buy rating on Intel with a $65 price target ahead of the company's June quarter results on July 25. Amid "broad-based softness" in the electronics end markets, Intel's business will be helped by improvement in the PC end market, ramping shipments of its Cascade Lake data center processors, and qualification of its 10nm technology, Wong tells investors in a pre-earnings research note. He expects continued Mobileye growth momentum and believes the 10nm ramp should help gross margin in the second half of the year.
07/15/19
RBCM
07/15/19
NO CHANGE
Target $41
RBCM
Underperform
RBC sees AMD continuing to take share in desktops, notebooks and servers
RBC Capital analyst Mitch Steves said that given PC data points that have been coming in positively, the question for Intel (INTC) is whether unit upside can offset share loss to AMD (AMD). The analyst, who thinks "more investors are near-term positive but long-term negative" on Intel, believes AMD will continue to gain share in both desktops and notebooks in the consumer market and thinks AMD can ramp up to 10% market share in servers by the end of this year. Steves keeps an Underperform rating on Intel shares.
QCOM Qualcomm
$75.93

0.9 (1.20%)

07/18/19
DAIW
07/18/19
INITIATION
Target $76
DAIW
Neutral
Qualcomm initiated with a Neutral yesterday at Daiwa
On July 17, Daiwa analyst Louis Miscioscia initiated Qualcomm with a Neutral rating and $76 price target. While 5G is coming and "will change how the world works with mobile connections [with] positive implications for many companies, and especially Qualcomm," a judge has ruled that Qualcomm violated the FTC Act and needs to change the core of its business model, said Miscioscia. Court rulings are "very unpredictable and will likely hold back multiple expansion," contended Miscioscia in his note yesterday.
07/18/19
LEHM
07/18/19
DOWNGRADE
Target $75
LEHM
Equal Weight
Barclays downgrades Qualcomm, sees range-bound stock into 2020
Barclays analyst Blayne Curtis downgraded Qualcomm to Equal Weight from Overweight and lowered his price target for the shares to $75 from $90. The analyst says that while Qualcomm remains one of the best 5G stories, he can't fully discount the potential for a worst case scenario that includes a failed appeal/change to license rates. As such, he believes the stock will be range-bound into next year. Further, in the near term, there is potential for downside to estimates since Huawei was never removed and the global handset market continues to be soft, Curtis tells investors in a research note.
07/18/19
RAJA
07/18/19
UPGRADE
RAJA
Outperform
Raymond James upgrades Apple, Skyworks on 5G iPhone expectations
As previously reported, Raymond James analyst Christopher Caso upgraded Apple (AAPL) to Outperform from Market Perform citing greater confidence in next year's 5G iPhone cycle. Since Apple has settled with Qualcomm (QCOM) and decided to use its modem in the 2020 iPhone, his checks have suggested that Apple has decided to offer 5G across the iPhone product line, including in its lower priced "R" models, said Caso, who thinks "a reasonably priced 5G phone will be a very compelling" reason to upgrade. Among chip suppliers, he believes Skyworks (SWKS) stands to gain the biggest incremental benefit from a stronger iPhone cycle and Caso also upgraded Skyworks shares to Outperform from Market Perform. He set a $250 price target on Apple shares and a $90 price target on Skyworks shares.
07/18/19
07/18/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Qualcomm (QCOM) and Skyworks (SWKS) downgraded to Equal Weight from Overweight at Barclays. 2. AMD (AMD) downgraded to Neutral from Buy at Mizuho with analyst Vijay Rakesh saying he continues to like AMD given its "solid" Ryzen/Rome portfolio and new product ramps, but he's downgrading the shares after a "stellar" 80% rally year-to-date. 3. BrightView (BV) downgraded to Neutral from Overweight at JPMorgan with analyst Judah Sokel saying he remains positive on the company's longer term potential, but he sees risk to estimates and prefers moving to the sidelines after the stock's year-to-date run of 75%. 4. MGM Resorts (MGM) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Thomas Allen saying he is concerned that Vegas, Macau, and its U.S. regional properties are all going to come in below his prior expectations. 5. Exxon Mobil (XOM) and Vermilion Energy (VET) downgraded to Sector Perform from Outperform at RBC Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
STLD Steel Dynamics
$31.55

0.09 (0.29%)

05/30/19
DBAB
05/30/19
DOWNGRADE
Target $30
DBAB
Hold
Steel Dynamics downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Chris Terry downgraded Steel Dynamics to Hold from Buy and lowered his price target for the shares to $30 from $44. The analyst made rating changes in the Steel and Service Centers space after reviewing his firm's pricing forecasts. Terry says that even though stocks have been already been under pressure, he's cautious on the near term for the Steel and Service Centers sub-sector. The analyst moved his recommendations to a more negative stance and sees value elsewhere, especially in precious metals.
06/27/19
DBAB
06/27/19
NO CHANGE
DBAB
Hold
Deutsche Bank places 'Catalyst Call' buy on Steel Dynamics
Deutsche Bank analyst Chris Terry placed a "Catalyst Call" buy on shares of Steel Dynamics (STLD) with the stock down 17% since late November 2018. The analyst keeps a Hold rating on the name but sees a shorter term opportunity for upside. Steel Dynamics is ~70% exposed to flat steel, where pricing is now likely bottoming, Terry tells investors in a research note. In addition, U.S. Steel (X) recently announced 2.5mt of capacity curtailments which could improve sentiment towards pricing and the future supply/demand balance, adds the analyst.
05/30/19
DBAB
05/30/19
DOWNGRADE
DBAB
Hold
Steel Dynamics downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Chris Terry downgraded Steel Dynamics to Hold from Buy to reflect a more negative stance on steel.
06/26/19
JEFF
06/26/19
NO CHANGE
JEFF
Nucor flat rolled price increase likely to help sentiment, says Jefferies
After Nucor (NUE) announced a $40/t flat rolled price increase yesterday, which was the first increase since February, Jefferies analyst Martin Englert said he thinks peers are likely to follow. While the increase may not immediately raise prices, it is a move in the right direction that aids more positive sector sentiment, Englert tell investors. The analyst, who advises investors to increase exposure to steel stocks, names Nucor, Steel Dynamics (STLD), Cleveland-Cliffs (CLF) and Commercial Metals (CMC) as his top U.S. picks Other publicly traded companies in the steel space include AK Steel (AKS), ArcelorMittal (MT), TimkenSteel (TMST) and U.S. Steel (X).
ZION Zions Bancorp
$45.16

-0.95 (-2.06%)

04/04/19
JPMS
04/04/19
DOWNGRADE
Target $50
JPMS
Neutral
Zions Bancorp downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Steven Alexopoulos downgraded Zions Bancorp to Neutral from Overweight and lowered his price target for the shares to $50 from $53.
02/21/19
BOFA
02/21/19
NO CHANGE
BOFA
BB&T added to US 1 List, Zions Bancorp removed at BofA/Merrill
06/14/19
UBSW
06/14/19
NO CHANGE
Target $52
UBSW
Neutral
Zions Bancorp earnings estimates lowered at UBS on weaker spread revenue
UBS analyst Brock Vandervliet kept his Neutral rating and $52 price target on Zions Bancorp but lowered his FY19 and FY20 EPS outlook by 12c and 3c to $4.42 and $4.88 respectively. The analyst says his recent meetings with the bank's management have left him more bullish on its small business lending position and technology investments, but he remains concerned over the near term about the "weaker spread revenue" across the sector.
04/04/19
JPMS
04/04/19
NO CHANGE
JPMS
JPMorgan downgrades Comerica, Zions and KeyCorp, upgrades Signature Bank
In an attempt to reduce interest rate "sensitivity," JPMorgan analyst Steven Alexopoulos downgraded Comerica (CMA), Zions Bancorp (ZION) and KeyCorp (KEY) to Neutral from Overweight and upgraded Signature Bank (SBNY) to Overweight from Neutral. The analyst says his bearish call on the bank sector "remains fully intact" even though the stock are "technically now much cheaper" since his October 2018 call. The tailwinds that helped bottom line growth for banks over the past several years will "fully start transitioning into headwinds" during 2019, Alexopoulos tells investors in a research note. He suggests repositioning portfolios away from asset sensitive banks while simultaneously increasing exposure to liability sensitive banks.
CDNS Cadence Design
$72.68

-0.21 (-0.29%)

05/14/19
WELS
05/14/19
INITIATION
WELS
Market Perform
Cadence Design initiated with a Market Perform at Wells Fargo
04/24/19
FBCO
04/24/19
NO CHANGE
Target $62
FBCO
Neutral
Cadence Design price target raised to $62 from $46 at Credit Suisse
Credit Suisse analyst John Pitzer raised his price target for Cadence Design to $62 from $46 following quarterly results as EDA structural story "marches on." The analyst reiterates a Neutral rating on the shares.
04/23/19
NEED
04/23/19
NO CHANGE
Target $71
NEED
Buy
Cadence Design price target raised to $71 from $64 at Needham
Needham analyst Richard Valera raised his price target on Cadence Design to $71 and kept his Buy rating after its "strong beat and raise" Q1 performance / FY19 outlook. The analyst notes that in spite of "some pockets of weakness", companies involved in AI/machine learning, 5G, and autonomous auto technologies continue to "invest aggressively in design tools" offered by Cadence Design. Valera adds that he is also positive on its entry into the "$4.5B system analysis market with a new 3D Solver product."
05/14/19
WELS
05/14/19
INITIATION
Target $68
WELS
Market Perform
Cadence Design initiated with a Market Perform at Wells Fargo
Wells Fargo analyst Gary Mobley started Cadence Design Systems with a Market Perform rating and $68 price target. While the analyst likes the company's long-term prospects, he's deterred by the current valuation with the shares within 10% of an all-time high.
SNPS Synopsys
$135.42

0.41 (0.30%)

07/12/19
KEYB
07/12/19
NO CHANGE
Target $152
KEYB
Overweight
Synopsys price target raised to $152 from $135 at KeyBanc
KeyBanc analyst Jason Celino raised his price target for Synopsys to $152 from $135 and maintained an Overweight rating after hosting CFO Trac Pham and VP Finance, Investor Relations, Lisa Ewbank. In a research note to investors, Celino says he came away from the meetings with increased confidence in the strength of EDA tailwinds and the company's margin expansion opportunities and that he remains a buyer.
05/14/19
WELS
05/14/19
INITIATION
WELS
Outperform
Synopsys initiated with an Outperform at Wells Fargo
04/11/19
RBCM
04/11/19
NO CHANGE
Target $140
RBCM
Top Pick
Synopsys price target raised to $140 from $130 at RBC Capital
RBC Capital analyst Mitch Steves raised his price target for Synopsys to $140 from $130 as upside case increases. After taking a more detailed look through the Synopsys Analyst Day deck, the analyst thinks the upside case for the company now stands at $6.50 EPS and that the stock could be worth about $175 in a more bullish scenario. Additionally, he has increased conviction in margin expansion due to the rising costs of SoC design, and thinks the software integrity business will remain profitable. The analyst reiterates a Top Pick rating on the shares.
05/14/19
WELS
05/14/19
INITIATION
Target $150
WELS
Outperform
Synopsys initiated with an Outperform at Wells Fargo
Wells Fargo analyst Gary Mobley started Synopsys with an Outperform rating and $150 price target. The company offers a "secure, defensible way" to invest in the long-term growth of the semiconductor and electronics systems industries, Mobley tells investors in a research note. The analyst likes the competitive dynamics in the electronic design automation market.
WHR Whirlpool
$148.30

0.085 (0.06%)

06/06/19
KEYB
06/06/19
UPGRADE
Target $150
KEYB
Overweight
Whirlpool upgraded to Overweight from Sector Weight at KeyBanc
KeyBanc analyst Ken Zener upgraded Whirlpool to Overweight from Sector Weight, with a $150 price target. While he readily admits "obvious upside catalysts are lacking," the analyst believes that his U.S.-centric thesis, coupled with already reduced expectations for North America volume, a long-term European margin recovery only now starting, and a lot of negative sentiment and news flow, is priced in the stock. Overall, Zener thinks Whirlpool remains a U.S. story, with Europe offering upside in time and with Asia the largest unknown variable given tariffs and/or other issues. Brazil remains a "black hole" of demand recovery, but at stable margins, he adds.
06/17/19
BUCK
06/17/19
NO CHANGE
Target $135
BUCK
Neutral
Appliance shipment data for May 'very strong,' says Buckingham
Buckingham analyst Megan McGrath noted that the Association of Home Appliance Manufacturers, or AHAM, reported May appliance shipments were up 3% overall and that the "AHAM 6 were up 10%. She calls the data "very strong" and noted that it was better than her expectations. McGrath has a Neutral rating on appliance maker Whirlpool with a $135 price target.
06/18/19
LBOW
06/18/19
NO CHANGE
LBOW
Buy
Longbow sees Whirlpool shares 'working back' to $145-$190 range
Longbow analyst David MacGregor noted that AHAM Core 6 shipments reported yesterday for May were up 9.9%, which was above his expectations. However, AHAM Core 6 shipments year-to-date are trending below Whirlpool's 2019 North American industry guidance of flat to down 2%, MacGregor pointed out. He still views the stock as attractive heading in the second half of the year and thinks Whirlpool shares can work back into the $145-$190 trading range that extended from 2015 through the first half of 2018. MacGregor keeps a Buy rating on Whirlpool shares.
07/17/19
BUCK
07/17/19
NO CHANGE
Target $150
BUCK
Neutral
Whirlpool price target raised to $150 from $135 at Buckingham
Buckingham analyst Megan McGrath raised her price target for Whirlpool to $150 from $135 and maintained a Neutral rating ahead of the company's second quarter earnings report. In a research note to investors, McGrath cites stabilizing North American appliance data, lower steel prices and her view that EMEA will begin to make progress on margin improvements this year for the price target increase.
AMTD TD Ameritrade
$52.41

0.82 (1.59%)

07/11/19
MSCO
07/11/19
DOWNGRADE
Target $53
MSCO
Equal Weight
Morgan Stanley downgrades TD Ameritrade to Equal Weight, prefers Charles Schwab
As previously reported, Morgan Stanley analyst Michael Cyprys downgraded TD Ameritrade (AMTD) to Equal Weight from Overweight ahead of Q2 reports from the North American brokers, stating that he sees a more challenging path to revenue growth given the less favorable interest rate and client cash environment. He lowered his EPS estimates across the discount broker stocks he covers by 4% on average for 2019 and by an average of 6% for 2020, noting that he cut his estimates the most for TD Ameritrade in 2020, lowering them by 11% due to lower yields and client cash balances. While 2019 is "shaping up to be a tough year for eBrokers' stocks," Cyprys said he sees Charles Schwab (SCHW) as best positioned for an upside surprise given what he views as "overly bearish" investor sentiment. He cut his price target on TD Ameritrade shares to $53 from $61, lowered his target on Charles Schwab shares to $46 from $53, and dropped his target on E-Trade (ETFC) shares to $55 from $61.
07/11/19
MSCO
07/11/19
DOWNGRADE
MSCO
Equal Weight
TD Ameritrade downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Michael Cyprys downgraded TD Ameritrade to Equal Weight from Overweight.
07/11/19
DBAB
07/11/19
NO CHANGE
DBAB
Deutsche starts 'Catalyst Call' pair trade of long Ameritrade, short Schwab
Deutsche Bank analyst Brian Bedell initiated a short-term "Catalyst Call" pair trade idea of long TD Ameritrade (AMTD) against Charles Schwab (SCHW). The analyst expects Ameritrade to outperform Schwab by at least ~5% through the Q2 earnings season.
04/24/19
DBAB
04/24/19
NO CHANGE
DBAB
Buy
TD Ameritrade selloff a good buying opportunity, says Deutsche Bank
Deutsche Bank analyst Brian Bedell views today's post-earnings selloff in shares of TD Ameritrade as a good buying opportunity. The stock in afternoon trading is down 4% to $52.03.
ACAD Acadia
$25.97

0.28 (1.09%)

05/01/19
PIPR
05/01/19
NO CHANGE
Target $35
PIPR
Overweight
Acadia price target raised to $35 from $30 at Piper Jaffray
Piper Jaffray analyst Danielle Brill raised her price target on Acadia to $35 and kept her Overweight rating after its better than expected Q1 sales of Nuplazid that was driven by "accelerated growth in new patient starts." The analyst further cites the management's increased FY19 Nuplazid midpoint sales guidance and also sees "significant unrealized value" for the company's dementia related psychosis programs.
06/11/19
PIPR
06/11/19
NO CHANGE
Target $35
PIPR
Overweight
Acadia risk/reward favorable into Phase 3 Enhance data, says Piper Jaffray
Piper Jaffray analyst Danielle Brill believes shares of Acadia Pharmaceuticals offer a favorable risk/reward into the Phase 3 Enhance trial of adjunctive Nuplazid for schizophrenia, which are expected by mid-2019. The analyst's level of conviction for a positive trial outcome remains low, but she believes investor expectations are also low and do not think the opportunity is currently reflected in Acadia's share value. She sees upside potential of 30%-35% on positive data with downside capped at 10% on a negative outcome. Brill keeps an Overweight rating on the shares with a $35 price target.
02/27/19
PIPR
02/27/19
NO CHANGE
Target $30
PIPR
Overweight
Acadia price target raised to $30 from $25 at Piper Jaffray
Piper Jaffray analyst Danielle Brill raised her price target for Acadia Pharmaceuticals to $30 following the company's Q4 results. The analyst expects Nuplazid' "modest" revenue growth to continue as safety concerns "slowly subside." She also anticipates a beneficial impact to 2019 sales from the ongoing direct-to-consumer campaign. As such, the company's fiscal 2019 guidance of $275M-$300M "appears in line and readily achievable," Brill tells investors in a post-earnings research note. With Acadia beginning two Phase 3 major depressive disorder trials in the first half of 2019, the analyst expects the shares to start reflecting value for the indication as the program continues to advance. She introduced probability-adjusted numbers at a 25% chance of success into her model and keeps an Overweight rating on Acadia.
02/27/19
ADAM
02/27/19
NO CHANGE
Target $27
ADAM
Hold
Canaccord says Acadia shares 'getting interesting,' raises price target to $27
Canaccord analyst Sumant Kulkarni said Acadia reported decent Q4 results, with Nuplazid sales coming in in-line with expectations. The outlook was solid, suggesting the media issues the drug faced are behind it, which is encouraging, said Kulkarni. With that out of the way, the analyst believes the stock is getting more interesting heading into data readouts for the company's dementia and schizophrenia drugs. Kulkarni maintained his Hold rating and raised his price target to $27 from $23 on Acadia shares.

TODAY'S FREE FLY STORIES

DB

Deutsche Bank

$6.98

-0.19 (-2.65%)

, COF

Capital One

$83.06

-2.68 (-3.13%)

17:57
08/23/19
08/23
17:57
08/23/19
17:57
Periodicals
Deutsche Bank, Capital One won't say if they have Trump's tax returns, NYP says »

Deutsche Bank (DB) and…

DB

Deutsche Bank

$6.98

-0.19 (-2.65%)

COF

Capital One

$83.06

-2.68 (-3.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

MXIM

Maxim Integrated

$52.14

-2.42 (-4.44%)

17:53
08/23/19
08/23
17:53
08/23/19
17:53
Hot Stocks
Maxim Integrated's Jain sells 12,683 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

GLD

SPDR Gold Shares

$144.15

2.77 (1.96%)

17:42
08/23/19
08/23
17:42
08/23/19
17:42
Hot Stocks
SPDR Gold Shares holdings rise to 859.83MT to 854.84MT »

This is the fourth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUMN

Golden Minerals

$0.27

0.0159 (6.38%)

17:33
08/23/19
08/23
17:33
08/23/19
17:33
Hot Stocks
Golden Minerals receives noncompliance notice from NYSE »

Golden Minerals announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DMPI

DelMar Pharmaceuticals

$0.77

0.0047 (0.61%)

17:25
08/23/19
08/23
17:25
08/23/19
17:25
Hot Stocks
Intracoastal Capital reports 9.99% passive stake in DelMar Pharmaceuticals »

Intracoastal Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTN

Raytheon

$180.58

-6.44 (-3.44%)

17:22
08/23/19
08/23
17:22
08/23/19
17:22
Hot Stocks
Raytheon awarded $534M Army contract »

Raytheon was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UHAL

Amerco

$339.43

-2.97 (-0.87%)

17:21
08/23/19
08/23
17:21
08/23/19
17:21
Hot Stocks
Amerco announces special cash dividend of 50c per share »

The dividend will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTLA

Intellia Therapeutics

$15.77

-1.08 (-6.41%)

17:20
08/23/19
08/23
17:20
08/23/19
17:20
Syndicate
Breaking Syndicate news story on Intellia Therapeutics »

Intellia Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$183.42

-4.19 (-2.23%)

17:19
08/23/19
08/23
17:19
08/23/19
17:19
Hot Stocks
General Dynamics awarded $1.08B Navy contract modification »

General Dynamics has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVLN

Novelion Therapeutics

$0.66

-0.0523 (-7.37%)

17:17
08/23/19
08/23
17:17
08/23/19
17:17
Hot Stocks
Stonepine Capital reports 6.1% passive stake in Novelion Therapeutics »

Stonepine Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$376.85

-8.91 (-2.31%)

17:14
08/23/19
08/23
17:14
08/23/19
17:14
Hot Stocks
Lockheed Martin awarded $2.43B Navy contract modification »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCS

OncoSec

$1.84

-0.03 (-1.60%)

17:14
08/23/19
08/23
17:14
08/23/19
17:14
Syndicate
Breaking Syndicate news story on OncoSec »

OncoSec files $50M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNXP

Tonix Pharmaceuticals

$0.42

-0.0249 (-5.60%)

17:09
08/23/19
08/23
17:09
08/23/19
17:09
Syndicate
Breaking Syndicate news story on Tonix Pharmaceuticals »

Tonix Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$284.86

-7.5 (-2.57%)

17:08
08/23/19
08/23
17:08
08/23/19
17:08
General News
Trump to raises tariff rates on Chinese goods, CNBC says »

U.S. President Donald…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$284.86

-7.5 (-2.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATIS

Attis Industries

$1.03

-0.08 (-7.21%)

17:06
08/23/19
08/23
17:06
08/23/19
17:06
Hot Stocks
Attis Industries provides update on status of Nasdaq listing »

Attis Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVEO

Civeo

$1.32

-0.07 (-5.04%)

17:04
08/23/19
08/23
17:04
08/23/19
17:04
Syndicate
Breaking Syndicate news story on Civeo »

Civeo files $300M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGO

Assured Guaranty

$42.56

-1.09 (-2.50%)

16:58
08/23/19
08/23
16:58
08/23/19
16:58
Hot Stocks
Assured Guaranty CEO sells 30,300 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMED

Ra Medical Systems

$1.87

-0.055 (-2.86%)

16:50
08/23/19
08/23
16:50
08/23/19
16:50
Hot Stocks
Ra Medical Systems discloses NYSE notice related to 10-Q filing delay »

Ra Medical Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBA

Pembina Pipeline

$35.73

-0.81 (-2.22%)

16:47
08/23/19
08/23
16:47
08/23/19
16:47
Syndicate
Breaking Syndicate news story on Pembina Pipeline »

Pembina Pipeline files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

APEN

Apollo Endosurgery

$3.50

(0.00%)

16:44
08/23/19
08/23
16:44
08/23/19
16:44
Syndicate
Breaking Syndicate news story on Apollo Endosurgery »

Apollo Endosurgery files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:40
08/23/19
08/23
16:40
08/23/19
16:40
General news
Fed's Clarida said the global economy has worsened »

Fed's Clarida said…

LQDA

Liquidia Technologies

$5.23

-0.38 (-6.77%)

16:35
08/23/19
08/23
16:35
08/23/19
16:35
Syndicate
Breaking Syndicate news story on Liquidia Technologies »

Liquidia Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

V

Visa

$175.24

-4.91 (-2.73%)

16:32
08/23/19
08/23
16:32
08/23/19
16:32
Hot Stocks
Visa CFO Prabhu sells over 25,000 class A common shares »

Visa vice chairman and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 27

    Oct

QCOM

Qualcomm

$73.57

-3.55 (-4.60%)

16:31
08/23/19
08/23
16:31
08/23/19
16:31
Hot Stocks
Qualcomm CFO Dave Wise to retire, Akash Palkhiwala named interim CFO »

Qualcomm announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 06

    Nov

ANFI

Amira Nature Foods

$0.58

-0.0144 (-2.44%)

16:30
08/23/19
08/23
16:30
08/23/19
16:30
Hot Stocks
Amira Nature Foods receives NYSE notice over late Form 20-F filing »

Amira Nature Food…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.